Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (204)
  2. Journal Article (120)
  3. Review (18)
  4. Research Letter (6)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (1)
Groups
  1. Adult Leukemia (356)
  2. Center for Hematologic Malignancies (356)
  3. Department of Medicine (356)
  4. Hematologic Malignancies, Division of (356)
  5. GSK Faculty (182)
  6. Hematologic Malignancies Research (140)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (83)
  3. Michel Sadelain (81)
  4. Martin Tallman (79)
  5. Maria Palomba (71)
  6. Xiuyan Wang (65)

More People

Years
  1. 2025 (19)
  2. 2024 (23)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (132)
  2. Journal of Clinical Oncology (30)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (146)
  2. Elsevier Inc. (34)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (29)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (356)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)
    Meeting Abstract

    Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Itacitinib for the prevention of immune effector cell therapy-associated cytokine release syndrome: Results from the phase 2 INCB 39110-211 placebo-controlled randomized cohort
    Meeting Abstract

    Frigault, M. J.; Maziarz, R. T.; Park, J. H.; Lazaryan, A.; Shah, N. N.; Svoboda, J.; Lekakis, L. J.; Reshef, R.; Phillips, C. L.; Burke, L. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Primary endpoint results from the BLISSPHALL study
    Meeting Abstract

    Geyer, M. B.; Mascarenhas, J.; Smith, M.; Pascual, S.; Shah, A.; Silvestrone, M. R.; Czaplinska, T.; Johnson, K.; Thompson, M. C.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Role of cell therapy product characteristics in patient response to TAK-940 (CD19(T2)28z1xx chimeric antigen receptor (CAR) T): Biomarker analyses from a phase i study in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Sundaresan, V.; Senechal, B.; Wang, X.; Kashyap, S.; Tong, E.; Joshi, A.; Dash, A.; Sellner, L.; Chen, S.; McAvoy, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cooperative CAR targeting to selectively eliminate AML and minimize escape
    Journal Article

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; de Stanchina, E.; Lopez, M.; Ng, M. R.; Fraser, K.; Subklewe, M.; more...
    Cancer Cell (2023)

    Fulltext@MSK | Save